Interstitial Lung Disease Clinical Trials

If you have idiopathic pulmonary fibrosis (IPF) or any other type of interstitial lung disease (ILD), you may qualify to participate in clinical trials conducted at Cedars-Sinai. By participating in clinical trials, you will have access to the latest medical and surgical techniques, backed by a respected team of specialists and researchers who have helped develop some of the latest treatments for ILD now used around the world.

Questions? See the Clinical Trials FAQs.

Condition:

Idiopathic pulmonary fibrosis

Key Inclusion Criteria

  • ≥40 years old
  • Diagnosed with IPF within four years of screening
  • Diagnosis of IPF is supported by high resolution computed tomography and historical surgical lung biopsy

Summary:

The purpose of this study is to determine the effects of an investigational drug called CC-90001 on patients diagnosed with idiopathic pulmonary fibrosis (IPF), a condition in which scarring of the lungs occurs. Participants will be randomly assigned to receive CC-90001 or placebo (inactive substance). Researchers will assess the effect of CC-90001 on improving IPF, in addition to how well the body tolerates the drug. Another purpose of the study is to determine whether a biomarker test can show how IPF is affected by CC-90001 in a specific group of cells in the body. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.

Condition:

Idiopathic pulmonary fibrosis

Key Inclusion Criteria

  • At least 40 years old
  • Women must be surgically sterile, postmenopausal or agree to use contraception; male subjects must agree to use one or more forms of birth control.
  • Diagnosis of IPF

Summary:

The purpose of this study is to evaluate the investigational use of a drug called BG00011 in patients with idiopathic pulmonary fibrosis (IPF) who are at least 40 years old. The study aims to determine the safety and effectiveness of the drug compared to placebo (inactive substance) in these patients. BG00011 is a laboratory-made antibody that is being developed to treat IPF. An antibody is a type of protein that is made by the body to help protect it from harmful substances. Participants will be randomly assigned to receive either BG00011 or placebo. Researchers also aim to learn whether a biomarker test will help determine the effects of BG00011 on the patient’s IPF. A biomarker is a biological molecule found in blood, other body fluids, or tissues that may be a sign of a condition or disease.

Condition:
Idiopathic pulmonary fibrosis

Key Inclusion Criteria:

  • Between 40 and 80 years old
  • Women of childbearing potential and all male participants must agree to use contraception
  • Features consistent with idiopathic pulmonary fibrosis (IPF) within 5 years prior to screening

Summary:
The purpose of this study is to evaluate the safety and tolerability of an experimental drug called TRK-250 after single and multiple inhaled doses in patients with idiopathic pulmonary fibrosis (IPF). TRK-250 is intended to inhibit the messages in the cell that create a protein involved in lung fibrosis (scarring). This study will be conducted in two parts, single inhaled dose (Part A) and multiple inhaled doses (Part B). Subjects in both parts will be randomly assigned to receive either TRK-250 or placebo (inactive substance). 

Condition:
Idiopathic pulmonary fibrosis

Key Inclusion Criteria:

  • Between 40 and 80 years old
  • Diagnosis of idiopathic pulmonary fibrosis (IPF) within 5 years

Summary:
This study focuses on individuals who have idiopathic pulmonary fibrosis (IPF) and are between 40 and 80 years old. The purpose of the study is to evaluate the safety of an experimental medication called ND‑L02‑s0201 when administered at two dose levels compared with placebo (inactive substance).

ND-L02-s0201 is made up of tiny particles of fat that also contain a small amount of RNA (ribonucleic acid) that is the active drug. The RNA in ND-L02-s0201 is designed to block the lungs from making a protein called "heat shock protein 47" (HSP47) for a limited period of time. It is thought that blocking the lungs from making HSP47 will help treat IPF because one of the roles of HSP47 is to help make collagen, which is involved in fibrosis (scarring).

Participation in the study will be approximately 40 weeks, including a screening and baseline period of up to 6 weeks, a treatment period of 24 weeks and a follow-up period of 10 weeks. Participants will attend 16-17 on-site visits at Cedars-Sinai and will receive an IV study drug infusion every 2 weeks at Cedars-Sinai during the treatment period.

Condition:
Idiopathic pulmonary fibrosis

Key Inclusion Criteria:

  • Currently taking nitendanib for 3-18 months
  • At least 40 years old at time of screening 

Summary:
The purpose of this study is to examine pulmonary rehabilitation in individuals with idiopathic pulmonary fibrosis (IPF) who are taking a medication called Ofev (nintedanib). The study aims to determine whether pulmonary rehabilitation improves the physical activities and quality of life in these patients. Pulmonary rehabilitation (PR) is a program that may include exercise, education and support to help improve the health of individuals with breathing diseases.

Specifically, the study will determine the difference in change from baseline assessment when PR is added to stable underlying Ofev therapy in patients with IPF; evaluate the difference in quality of life when PR is added to stable underlying Ofev therapy; and determine whether PR has an enduring effect when added to stable underlying Ofev therapy.

Participants will be randomly assigned to one of two study groups. The first group will receive pulmonary rehabilitation several times a week for 12 weeks at the Cedars-Sinai Pulmonary Rehabilitation Program; the second group will not receive pulmonary rehabilitation. All participants will continue to take Ofev as prescribed.